.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XH04_Belinostat.Belinostat .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XH04_Belinostat.Belinostat| name: | Belinostat |
| ATC code: | L01XH04 | route: | intravenous |
| n-compartments | 2 |
Belinostat is a histone deacetylase (HDAC) inhibitor used primarily for the treatment of relapsed or refractory peripheral T-cell lymphoma. It has received FDA approval for this indication and is used as an antineoplastic agent in oncology.
Population pharmacokinetics in adult patients with advanced solid tumors or hematologic malignancies following intravenous infusion. The study population included both male and female patients.
Peer, CJ, et al., & Figg, WD (2018). A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat. Cancer chemotherapy and pharmacology 82(3) 565–570. DOI:10.1007/s00280-018-3631-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29951694
Peer, CJ, et al., & Figg, WD (2016). UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation. Journal of clinical pharmacology 56(4) 450–460. DOI:10.1002/jcph.627 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26637161
Shafer, D, et al., & Grant, S (2023). Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies. Cancer chemotherapy and pharmacology 91(3) 281–290. DOI:10.1007/s00280-023-04511-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36864346